Option Exercise Fee. Notwithstanding anything to the contrary in Section 4.1 of the Agreement, GSK may exercise its GSK Program Option for the Anti-Notch 1 Program within [***] by providing written notice in accordance with Section 4.1.3(a) of the Agreement of such GSK Program Option exercise to OncoMed. If [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. GSK exercises its GSK Program Option in accordance with this Paragraph 7.3, GSK shall pay to OncoMed the one-time GSK Program Option exercise fee of [***]. OncoMed shall invoice GSK for such GSK Program Option exercise fee on or after receipt from GSK of GSK’s notice of exercise of such GSK Program Option and GSK shall pay the GSK Program Option exercise fee to OncoMed within [***] after receipt of an invoice therefor from OncoMed. If GSK does not exercise its GSK Program Option for the Anti- Notch 1 Program in accordance with this Paragraph 7.3, then Section 4.1.5 of the Agreement shall apply with respect to such Program.
Appears in 1 contract
Samples: Research and Development Collaboration, Option, and License Agreement (OncoMed Pharmaceuticals Inc)
Option Exercise Fee. Notwithstanding anything to the contrary in Section 4.1 of the Agreement, GSK may elect to exercise its GSK Program Option for the Anti-Notch 1 Program within [***] with respect thereto by providing written notice in accordance with Section 4.1.3(a) of the Agreement of such GSK Program Option exercise to OncoMed. If GSK elects to exercise its GSK Program Option in accordance with this Paragraph 5.4.2(b), GSK shall pay to OncoMed the one-time GSK Program Option exercise fee for the Anti-Notch 1 Program of [***]. OncoMed shall invoice GSK for such GSK Program Option exercise fee on or after receipt from GSK of GSK’s notice of exercise of such GSK Program Option [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. GSK exercises its GSK Program Option in accordance with this Paragraph 7.3, GSK shall pay to OncoMed the one-time GSK Program Option exercise fee of [***]. OncoMed shall invoice GSK for such GSK Program Option exercise fee on or after receipt from GSK of GSK’s notice of exercise of such GSK Program Option and GSK shall pay the such GSK Program Option exercise fee to OncoMed within [***] after receipt of an invoice therefor from OncoMed. If GSK does not exercise its GSK Program Option for the Anti- Notch 1 Program in accordance with this Paragraph 7.35.4, then Section 4.1.5 of the Agreement shall apply with respect to such the Anti-Notch 1 Program.
Appears in 1 contract
Samples: Research and Development Collaboration, Option, and License Agreement (OncoMed Pharmaceuticals Inc)
Option Exercise Fee. Notwithstanding anything to the contrary in Section 4.1 of the Agreement, GSK may exercise its GSK Program Option for the Anti-Notch 1 Program within [***] by providing written notice in accordance with Section 4.1.3(a) of the Agreement of such GSK Program Option exercise to OncoMed. If [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. GSK exercises its GSK Program Option in accordance with this Paragraph 7.3, GSK shall pay to OncoMed the one-time GSK Program Option exercise fee of [***]. OncoMed shall invoice GSK for such GSK Program Option exercise fee [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. on or after receipt from GSK of GSK’s notice of exercise of such GSK Program Option and GSK shall pay the GSK Program Option exercise fee to OncoMed within [***] after receipt of an invoice therefor from OncoMed. If GSK does not exercise its GSK Program Option for the Anti- Notch 1 Program in accordance with this Paragraph 7.3, then Section 4.1.5 of the Agreement shall apply with respect to such Program.
Appears in 1 contract
Samples: Research and Development Collaboration, Option, and License Agreement (OncoMed Pharmaceuticals Inc)
Option Exercise Fee. Notwithstanding anything to the contrary in Section 4.1 of the Agreement, GSK may elect to exercise its GSK Program Option for the Anti-Notch 1 Program within [***] with respect thereto by providing written notice in accordance with Section 4.1.3(a) of the Agreement of such GSK Program Option exercise to OncoMed. If [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect GSK elects to the omitted portions. GSK exercises exercise its GSK Program Option in accordance with this Paragraph 7.35.4.2(b), GSK shall pay to OncoMed the one-time GSK Program Option exercise fee for the Anti-Notch 1 Program of [***]. OncoMed shall invoice GSK for such GSK Program Option exercise fee on or after receipt from GSK of GSK’s notice of exercise of such GSK Program Option and GSK shall pay the such GSK Program Option exercise fee to OncoMed within [***] after receipt of an invoice therefor from OncoMed. If GSK does not exercise its GSK Program Option for the Anti- Notch 1 Program in accordance with this Paragraph 7.35.4, then Section 4.1.5 of the Agreement shall apply with respect to such the Anti-Notch 1 Program.
Appears in 1 contract
Samples: Research and Development Collaboration, Option, and License Agreement (OncoMed Pharmaceuticals Inc)